FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169968952> ?p ?o ?g. }

• W2169968952 endingPage "e83759" @default.
• W2169968952 startingPage "e83759" @default.
• W2169968952 abstract "HMG Co-A reductase inhibitors are ubiquitous in our community yet their potential role in age-related macular degeneration (AMD) remains to be determined.To evaluate the effect of simvastatin on AMD progression and the effect modification by polymorphism in apolipoprotein E (ApoE) and complement factor H (CFH) genes.A proof of concept double-masked randomized controlled study.114 participants aged 53 to 91 years, with either bilateral intermediate AMD or unilateral non-advanced AMD (with advanced AMD in fellow eye), BCVA ≥ 20/60 in at least one eye, and a normal lipid profile.Simvastatin 40 mg/day or placebo, allocated 1:1.Progression of AMD either to advanced AMD or in severity of non-advanced AMD. Results. The cumulative AMD progression rates were 70% in the placebo and 54% in the simvastatin group. Intent to treat multivariable logistic regression analysis, adjusted for age, sex, smoking and baseline AMD severity, showed a significant 2-fold decrease in the risk of progression in the simvastatin group: OR 0.43 (0.18-0.99), p = 0.047. Post-hoc analysis stratified by baseline AMD severity showed no benefit from treatment in those who had advanced AMD in the fellow eye before enrolment: OR 0.97 (0.27-3.52), p = 0.96, after adjusting for age, sex and smoking. However, there was a significant reduction in the risk of progression in the bilateral intermediate AMD group compared to placebo [adjusted OR 0.23 (0.07-0.75), p = 0.015]. The most prominent effect was observed amongst those who had the CC (Y402H) at risk genotype of the CFH gene [OR 0.08 (0.02-0.45), p = 0.004]. No evidence of harm from simvastatin intervention was detected.Simvastatin may slow progression of non-advanced AMD, especially for those with the at risk CFH genotype CC (Y402H). Further exploration of the potential use of statins for AMD, with emphasis on genetic subgroups, is warranted.Australian New Zealand Clinical Trial Registry (ANZCTR) ACTRN1260500032065." @default.
• W2169968952 created "2016-06-24" @default.
• W2169968952 creator A5000482514 @default.
• W2169968952 creator A5035555741 @default.
• W2169968952 creator A5048649589 @default.
• W2169968952 creator A5051997081 @default.
• W2169968952 creator A5060585327 @default.
• W2169968952 creator A5060938760 @default.
• W2169968952 creator A5061915670 @default.
• W2169968952 creator A5064377356 @default.
• W2169968952 creator A5067204911 @default.
• W2169968952 creator A5070294227 @default.
• W2169968952 date "2013-12-31" @default.
• W2169968952 modified "2023-10-18" @default.
• W2169968952 title "Proof of Concept, Randomized, Placebo-Controlled Study of the Effect of Simvastatin on the Course of Age-Related Macular Degeneration" @default.
• W2169968952 cites W127809968 @default.
• W2169968952 cites W1522272765 @default.
• W2169968952 cites W1580351516 @default.
• W2169968952 cites W159419684 @default.
• W2169968952 cites W1700167397 @default.
• W2169968952 cites W180947891 @default.
• W2169968952 cites W1922994408 @default.
• W2169968952 cites W1963996422 @default.
• W2169968952 cites W1968012352 @default.
• W2169968952 cites W1972642682 @default.
• W2169968952 cites W1988191877 @default.
• W2169968952 cites W1988804690 @default.
• W2169968952 cites W2005450539 @default.
• W2169968952 cites W2019325581 @default.
• W2169968952 cites W2025176768 @default.
• W2169968952 cites W2026362028 @default.
• W2169968952 cites W2041745079 @default.
• W2169968952 cites W2064260525 @default.
• W2169968952 cites W2069110097 @default.
• W2169968952 cites W2073741050 @default.
• W2169968952 cites W2078603028 @default.
• W2169968952 cites W2083565595 @default.
• W2169968952 cites W2089946654 @default.
• W2169968952 cites W2115177638 @default.
• W2169968952 cites W2123883528 @default.
• W2169968952 cites W2125149319 @default.
• W2169968952 cites W2137983259 @default.
• W2169968952 cites W2139029875 @default.
• W2169968952 cites W2144469043 @default.
• W2169968952 cites W2144896295 @default.
• W2169968952 cites W2151289732 @default.
• W2169968952 cites W2156434735 @default.
• W2169968952 cites W2166402646 @default.
• W2169968952 cites W2167734104 @default.
• W2169968952 cites W2419255724 @default.
• W2169968952 cites W2598520882 @default.
• W2169968952 cites W4244908295 @default.
• W2169968952 cites W4254421138 @default.
• W2169968952 doi "https://doi.org/10.1371/journal.pone.0083759" @default.
• W2169968952 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3877099" @default.
• W2169968952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24391822" @default.
• W2169968952 hasPublicationYear "2013" @default.
• W2169968952 type Work @default.
• W2169968952 sameAs 2169968952 @default.
• W2169968952 citedByCount "63" @default.
• W2169968952 countsByYear W21699689522014 @default.
• W2169968952 countsByYear W21699689522015 @default.
• W2169968952 countsByYear W21699689522016 @default.
• W2169968952 countsByYear W21699689522017 @default.
• W2169968952 countsByYear W21699689522018 @default.
• W2169968952 countsByYear W21699689522019 @default.
• W2169968952 countsByYear W21699689522020 @default.
• W2169968952 countsByYear W21699689522021 @default.
• W2169968952 countsByYear W21699689522022 @default.
• W2169968952 countsByYear W21699689522023 @default.
• W2169968952 crossrefType "journal-article" @default.
• W2169968952 hasAuthorship W2169968952A5000482514 @default.
• W2169968952 hasAuthorship W2169968952A5035555741 @default.
• W2169968952 hasAuthorship W2169968952A5048649589 @default.
• W2169968952 hasAuthorship W2169968952A5051997081 @default.
• W2169968952 hasAuthorship W2169968952A5060585327 @default.
• W2169968952 hasAuthorship W2169968952A5060938760 @default.
• W2169968952 hasAuthorship W2169968952A5061915670 @default.
• W2169968952 hasAuthorship W2169968952A5064377356 @default.
• W2169968952 hasAuthorship W2169968952A5067204911 @default.
• W2169968952 hasAuthorship W2169968952A5070294227 @default.
• W2169968952 hasBestOaLocation W21699689521 @default.
• W2169968952 hasConcept C118487528 @default.
• W2169968952 hasConcept C126322002 @default.
• W2169968952 hasConcept C141071460 @default.
• W2169968952 hasConcept C142724271 @default.
• W2169968952 hasConcept C151956035 @default.
• W2169968952 hasConcept C168563851 @default.
• W2169968952 hasConcept C204787440 @default.
• W2169968952 hasConcept C27081682 @default.
• W2169968952 hasConcept C2776329913 @default.
• W2169968952 hasConcept C2776403814 @default.
• W2169968952 hasConcept C67761136 @default.
• W2169968952 hasConcept C71924100 @default.
• W2169968952 hasConcept C90924648 @default.
• W2169968952 hasConceptScore W2169968952C118487528 @default.
• W2169968952 hasConceptScore W2169968952C126322002 @default.
• W2169968952 hasConceptScore W2169968952C141071460 @default.

• next